PT3545948T - Utilização de aglomerado de ouro ou substância que contém aglomerado de ouro na preparação de droga para prevenção e/ou tratamento de glaucoma - Google Patents

Utilização de aglomerado de ouro ou substância que contém aglomerado de ouro na preparação de droga para prevenção e/ou tratamento de glaucoma

Info

Publication number
PT3545948T
PT3545948T PT178738266T PT17873826T PT3545948T PT 3545948 T PT3545948 T PT 3545948T PT 178738266 T PT178738266 T PT 178738266T PT 17873826 T PT17873826 T PT 17873826T PT 3545948 T PT3545948 T PT 3545948T
Authority
PT
Portugal
Prior art keywords
gold cluster
drug
preventing
preparation
containing substance
Prior art date
Application number
PT178738266T
Other languages
English (en)
Original Assignee
Shenzhen Profound View Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Profound View Pharma Tech Co Ltd filed Critical Shenzhen Profound View Pharma Tech Co Ltd
Publication of PT3545948T publication Critical patent/PT3545948T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6941—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a granulate or an agglomerate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Ceramic Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
PT178738266T 2016-11-28 2017-11-27 Utilização de aglomerado de ouro ou substância que contém aglomerado de ouro na preparação de droga para prevenção e/ou tratamento de glaucoma PT3545948T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611062360 2016-11-28

Publications (1)

Publication Number Publication Date
PT3545948T true PT3545948T (pt) 2021-09-10

Family

ID=62194814

Family Applications (1)

Application Number Title Priority Date Filing Date
PT178738266T PT3545948T (pt) 2016-11-28 2017-11-27 Utilização de aglomerado de ouro ou substância que contém aglomerado de ouro na preparação de droga para prevenção e/ou tratamento de glaucoma

Country Status (10)

Country Link
US (3) US11413355B2 (pt)
EP (1) EP3545948B1 (pt)
JP (2) JP7032616B2 (pt)
CN (2) CN111588733B (pt)
AU (1) AU2017366624B2 (pt)
DK (1) DK3545948T3 (pt)
ES (1) ES2886943T3 (pt)
HU (1) HUE055873T2 (pt)
PT (1) PT3545948T (pt)
WO (1) WO2018095429A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2886943T3 (es) * 2016-11-28 2021-12-21 Shenzhen Profound View Pharma Tech Co Ltd Uso de clúster de oro o sustancia que contiene clúster de oro en la preparación de fármacos para prevenir y/o tratar el glaucoma
WO2020147029A1 (en) 2019-01-16 2020-07-23 Shenzhen Vast Conduct Science Research Co., Ltd. Copper nanoclusters, thymine-modified hyaluronic acid and poly (copper nanoclusters), method for preparing the same, and application thereof
TWI759610B (zh) * 2019-06-27 2022-04-01 晶碩光學股份有限公司 具有角膜修護功能的眼用產品
TWI801618B (zh) * 2019-06-27 2023-05-11 晶碩光學股份有限公司 具有抗氧化功能的隱形眼鏡產品
US12310985B2 (en) 2019-10-18 2025-05-27 Shenzhen Profound View Pharmaceutical Technology Composition and method for treatment of diabetes
CN112675196B (zh) * 2019-10-18 2023-05-16 深圳深见医药科技有限公司 用于治疗糖尿病的组合物和方法
WO2021072747A1 (en) * 2019-10-18 2021-04-22 Shenzhen Profound View Pharmaceutical Technology Co., Ltd. Composition and method for treatment of diabetes
EP4045063B1 (en) * 2019-12-27 2024-10-02 Wuhan Vast Conduct Science Foundation Co., Ltd. Composition and method for treatment of multiple sclerosis
AU2020436820B2 (en) * 2020-03-16 2024-05-02 Wuhan Vast Conduct Science Foundation Co., Ltd. Copper clusters, composition, and method for treatment of liver cirrhosis
KR102903284B1 (ko) * 2020-03-16 2025-12-23 우한 바스트 컨덕트 사이언스 파운데이션 컴퍼니 리미티드 간경변증의 치료를 위한 금 클러스터(AuCs) 및 조성물
KR102927722B1 (ko) * 2020-05-09 2026-02-19 선전 프로파운드 뷰 파마슈티칼 테크놀로지 컴퍼니 리미티드 비정형 항정신병약물에 의해 유발되는 부작용의 치료
CN114432340B (zh) * 2020-11-03 2023-06-23 北京工业大学 一种Au与抗凋亡蛋白拮抗肽的复合物制备以及协同诱导肿瘤细胞凋亡的应用
EP4203975A4 (en) * 2020-11-27 2024-01-03 Shenzhen Profound View Pharmaceutical Technology Co., Ltd. GOLD CLUSTER, COMPOSITIONS AND METHODS FOR TREATING CEREBRAL ISCHEMIC STROKE
CN116421739B (zh) * 2020-11-27 2026-03-06 深圳深见医药科技有限公司 治疗脑卒中的金团簇、组合物和方法
CN112509648B (zh) * 2020-11-27 2022-09-09 易波 一种用于吸持生物组织的亲水界面
JP7750970B2 (ja) * 2021-02-19 2025-10-07 エルエー アイ エルエルシー 眼球の軸方向長さ及び曲率を修正するためのブドウ腫支持デバイス及び方法
JP2025503046A (ja) * 2022-01-20 2025-01-30 深▲セン▼深見医薬科技有限公司 Ｌ－Ｎ－イソブチリルシステイン（Ｌ－ＮＩＢＣ）結合金クラスターＡｕ１８（Ｌ－ＮＩＢＣ）１４、その組成物及び利用
WO2023137671A1 (en) * 2022-01-20 2023-07-27 Shenzhen Profound View Pharmaceutical Technology Co., Ltd. L-n-isobutyryl cysteine (l-nibc) -bound gold cluster au 15 (l-nibc) 13, compositions and applications thereof
CN116064031B (zh) * 2022-12-31 2025-02-14 哈尔滨师范大学 聚集诱导发光型金纳米簇的合成及其应用
CN116496786B (zh) * 2023-07-01 2023-09-29 北京建工环境修复股份有限公司 一种钆纳米簇荧光探针及其在环境检测方面的应用
CN119424497B (zh) * 2025-01-08 2025-06-24 万邦德制药集团有限公司 一种用于防治阿尔茨海默病、皮肤光老化的组合物、制剂及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3859882B2 (ja) 1998-09-14 2006-12-20 株式会社リコー 新規なオリゴフェロセニレン誘導体及び電気化学的に活性なクラスター薄膜の製造方法
US6989007B2 (en) * 2001-02-21 2006-01-24 Solx, Inc. Devices and techniques for treating glaucoma
US8211656B2 (en) * 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
US20170157038A1 (en) * 2008-11-13 2017-06-08 Gholam A. Peyman Ophthalmic drug delivery method
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
CN103006565B (zh) * 2011-09-28 2014-12-10 国家纳米科学中心 一种纳米颗粒药物组合物及其制备方法
BRPI1106368B1 (pt) * 2011-10-28 2020-12-22 Fundação Educacional De Criciuma - Fucri colírio para tratamento de processo inflamatório intra-ocular
WO2014164519A1 (en) * 2013-03-12 2014-10-09 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for inhibiting the effects of amyloid beta oligomers
WO2015069669A1 (en) * 2013-11-05 2015-05-14 Elena Molokanova Nanostructure conjugates for modulation of location-specific subtypes of receptors and ion channels
CN105061561B (zh) * 2015-07-21 2019-03-26 天津大学 用于抑制β淀粉样蛋白聚集的多肽和多肽功能化的金纳米粒子及制备和应用
ITUA20163432A1 (it) * 2016-05-13 2017-11-13 Fondazione St Italiano Tecnologia Processo per la preparazione di nanoparticelle cave con un core metallico
CN106370640B (zh) * 2016-11-25 2019-07-05 西南大学 碳点-金簇复合荧光纳米探针及其应用
ES2886943T3 (es) 2016-11-28 2021-12-21 Shenzhen Profound View Pharma Tech Co Ltd Uso de clúster de oro o sustancia que contiene clúster de oro en la preparación de fármacos para prevenir y/o tratar el glaucoma
CA3043775A1 (en) * 2016-12-06 2018-06-14 Universite Laval Ultrastable gold nanoparticles for drug delivery applications and synthesis thereof

Also Published As

Publication number Publication date
EP3545948A1 (en) 2019-10-02
AU2017366624A1 (en) 2019-05-02
AU2017366624B2 (en) 2020-10-08
US12377167B2 (en) 2025-08-05
US20240238443A1 (en) 2024-07-18
WO2018095429A1 (zh) 2018-05-31
DK3545948T3 (da) 2021-09-20
ES2886943T3 (es) 2021-12-21
US11413355B2 (en) 2022-08-16
HUE055873T2 (hu) 2022-01-28
EP3545948B1 (en) 2021-08-11
US11969477B2 (en) 2024-04-30
CN111588733A (zh) 2020-08-28
CN108113997A (zh) 2018-06-05
JP2022046625A (ja) 2022-03-23
HK1250486A1 (zh) 2018-12-21
US20220323608A1 (en) 2022-10-13
CN111588733B (zh) 2022-08-12
CN108113997B (zh) 2020-07-07
JP2020500858A (ja) 2020-01-16
US20190175753A1 (en) 2019-06-13
EP3545948A4 (en) 2020-07-08
JP7361411B2 (ja) 2023-10-16
JP7032616B2 (ja) 2022-03-09

Similar Documents

Publication Publication Date Title
PT3545948T (pt) Utilização de aglomerado de ouro ou substância que contém aglomerado de ouro na preparação de droga para prevenção e/ou tratamento de glaucoma
IL285179A (en) Pharmaceutical preparations containing synthetic glycans for use in the treatment of diseases of the digestive system and methods and methods for their preparation
IL287749A (en) Compositions for administering implantable drugs and methods of their use
IL262831B1 (en) Medical implants and methods for their preparation
PL3377637T3 (pl) Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry
IL264301A (en) Treatment of Fabry disease in ert-naive and ert-experienced patients
GB201411465D0 (en) Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer
IL254377B (en) Selective akr1c3 reductase activated prodrugs and their use for treating cancer patients
IL251003A0 (en) Anisotropic biocomposite materials, medical implants and treatment methods from these materials
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
EP3337482A4 (en) TRANSDERMAL FORMULATIONS FOR THE DISTRIBUTION OF BERBERIN COMPOUNDS AND THEIR USE IN THE TREATMENT OF BERBER INDEPENDENT ILLNESSES AND DISORDERS
IL263227A (en) Drug-delivery nanoparticles and treatments for drug-resistant cancer
IL266623A (en) A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer
EP3169321A4 (en) Propolis and extracts thereof for the treatment of skin cancers and improvement of skin health
EP3290034A4 (en) Use of trimethazine in preparation of drugs for preventing and treating liver diseases
LT3168214T (lt) Pakeisti 2-tiokso-imidazolidin-4-onai ir jų spiro analogai, aktyvi priešvėžinė sudedamoji dalis, farmacinė kompozicija, medicininis paruošimas, prostatos vėžio gydymo būdas
SG11202000423XA (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
IL266486A (en) Pharmaceutical preparations and methods for cancer treatment
IL264407A (en) Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases
IL245769A0 (en) A device for administering a drug and a method of using it
IL270159B (en) Preparations containing nanometer particles for the administration of drugs for the treatment of eye diseases
EP3344233A4 (en) TRANSDERMAL FORMULATIONS FOR THE DELIVERY OF DOXYCLYCLIN AND THEIR USE IN THE TREATMENT OF DOXYCLYCLIN-RELATED ILLNESSES AND SUFFERING
PT3215143T (pt) Combinação compreendendo espirulina e palmitoíletanolamida
ZA201907334B (en) Use of berberine or active metabolite thereof in preparation of drug for preventing and/or treating phenylketonuria
SG11201704430SA (en) Preventive and/or therapeutic agent of immune disease